Global Offshore Wind Transmission Report 2021: Growth Drivers, Cost Competitiveness, Offshore Wind’s Promising Attributes, Targets And Mandates, Policy And Regulatory Developments

Published by
The Street

By PR Newswire DUBLIN, Jan. 7, 2022 /PRNewswire/ — The “Offshore Wind Transmission Report” report has been added to ResearchAndMarkets.com’s offering. Global Transmission Research Report analyses the market size and opportunity for offshore wind transmission across the globe. The report provides an overview of the recent policy developments and mandates for offshore wind development, examine the costs and present the various models and technology options for developing offshore wind transmission infrastructure. It provides information on existing and planned offshore transmission projects and… Continue reading “Global Offshore Wind Transmission Report 2021: Growth Drivers, Cost Competitiveness, Offshore Wind’s Promising Attributes, Targets And Mandates, Policy And Regulatory Developments”

Review: Testing Askov Finlayson’s Climate-Positive Winter Parka

Published by
InsideHook

By Alex Lauer Back on a blustery November day in 2013, I stopped by the roving menswear pop-up Northern Grade during its stop in a warehouse in Minneapolis. While there were all manner of American-made goods for sale, my girlfriend and I picked up a couple pom-pom-topped beanies emblazoned with the word “North” from local shop Askov Finlayson. They had just started releasing their own clothes, and we wanted to support a local business. We had never thought of our state as “the North,” we just thought it was too damn cold for the middle of November, and the hats were warm. Cut to Super Bowl 52,… Continue reading “Review: Testing Askov Finlayson’s Climate-Positive Winter Parka”

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

Translational studies performed at the European Institute for Molecular Imaging and the Department of Nuclear Medicine (University and University Hospital of Münster) show rapid and selective tumor uptake of OncoFAP with unprecedented selectivity against healthy organs in cancer patients

Philogen, in collaboration with Senn Chemicals, has already produced the equivalent of 1 million GMP doses of clinical-grade OncoFAP-DOTAGA

Siena, Italy, January 7th, 2022 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, announces that its wholly-owned Swiss subsidiary, Philochem AG, has co-authored a new translational study on 68Ga-OncoFAP, a best-in-class FAP-targeting small molecule for applications in cancer and inflammation.

The paper, entitled “Translational imaging of the fibroblast activation protein (FAP) using the new ligand “[68Ga]Ga-OncoFAP-DOTAGA”, was published in the peer-reviewed journal European Journal of Nuclear Medicine and Molecular Imaging and reports the novel pre-clinical and clinical findings obtained with 68Ga-OncoFAP.

The data confirmed the rapid and selective accumulation of 68Ga-OncoFAP in solid tumor lesions in disease models and in patient cases. Additionally, 68Ga-OncoFAP showed excellent selectivity against healthy organs, including kidneys, at early time points (i.e., already one hour after systemic administration) and an impressive tumor-targeting performance in mice and in patients with different stages of disease (i.e., from localized to disseminated disease).

Dario Neri, Chief Executive Officer of Philogen commented: “We are delighted with the translational results presented in our recent paper which showed OncoFAP’s strong selectivity against healthy organs in cancer patients. In order to pave the way towards a broader adoption of this technology, we have established a network of Nuclear Medicine centers across various continents to support our future clinical studies. The equivalent of 1,000,000 GMP-grade doses of OncoFAP-DOTAGA has already been produced in collaboration with Senn Chemicals.”

The results presented in this article stem from a collaboration between the European Institute for Molecular Imaging and the Department of Nuclear Medicine at the University and University Hospital of Münster and the scientists at Philochem AG.

OncoFAP has been manufactured in GMP conditions at Senn Chemicals AG, a CDMO in peptide synthesis and small molecules with expertise in small scale GMP production.

Fibroblast Activation Protein (FAP) has recently emerged as a tumor-associated antigen with abundant and selective expression in the majority of human solid malignancies. The discovery of OncoFAP, together with its preclinical characterization, has been recently reported in Proc Natl Acad Sci USA in April 2021.

Philochem’s OncoFAP-derivates are the small organic ligands with the highest affinity to the FAP antigen reported to date.

OncoFAP is currently being studied as modular component for the generation of therapeutic products enabling the targeted delivery of a potent beta-emitter (lutetium-177), of fluorescein-specific CAR T-cells, and of highly cytotoxic auristatin derivatives.

The article can be accessed from the European Journal of Nuclear Medicine and Molecular Imaging website under the following link.

About Philogen

Philogen is a Swiss-Italian clinical-stage biotechnology company listed on the Italian Stock Exchange. It is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen’s strategy is to deliver bioactive agents, for example cytokines or drugs, to the site of disease using antibodies and other ligands that specifically and efficiently target stromal antigens. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com and www.philochem.com.

Philogen contacts

Dr. Christian Lizak (Business Development), christian.lizak@philogen.com

Dr. Emanuele Puca (Investor Relations), emanuele.puca@philogen.com

+41 (0) 43 544 88 00

Consilium Strategic Communications contacts

Mary-Jane Elliott, Davide Salvi

Philogen@consilium-comms.com

Amlan International Continues APEC Region Expansion by Kim Huang Appointed Regional Technical Services Manager

Kim Huang

Kim Huang appointed regional technical services manager in Asia-Pacific for Amlan International.

CHICAGO, Jan. 06, 2022 (GLOBE NEWSWIRE) — Amlan International, a global leader in natural, mineral-based feed additives for poultry and livestock, has broadened their technical capabilities in the Asia Pacific (APEC) region with the appointment of Dr. Kim Huang as regional technical services manager.

Kim will play an important role in expanding the APEC team that will serve the growing Southeast Asia market where poultry production is expected to account for one-third of global production by 2023. Kim will use his wide-ranging nutrition, poultry and feed-additive experience to help animal protein producers in the APEC region successfully incorporate Amlan’s novel mineral-based feed additives to maintain animal health, improve feed efficiency and achieve their production and business goals.

Input costs for producers are increasing, making improved feed conversion rates and healthy animals even more important for profitability. As regional technical services manager, Kim will be a key technical resource and deliver superior service to ensure long-term customer value and productivity. Kim will work to expand the service experiences for Amlan customers by providing them with mineral-based solutions that can help improve production efficiencies and profitability.

“Kim’s extensive technical service experience in the APEC region will provide our customers with valuable knowledge and expertise on the benefits of incorporating our novel mineral-based feed additives into their poultry and livestock operations,” says Fred Kao, Vice President of Global Sales, Amlan International. “We are extremely excited to welcome Kim to the team and look forward to the opportunities he will bring to Amlan and our customers.”

Kim has been involved in the animal nutrition industry for more than 30 years, including most recently as a nutritional consultant for poultry businesses. Previously, he was a technical and commercial director for the Asia Pacific for a global feed and nutrition technology company subsidiary, and a nutritional services manager for the Asia Pacific for a global poultry breeding company.

“Consumer demands for natural, antibiotic-free animal protein are growing around the world,” says Dan Jaffee, President and CEO, Oil-Dri Corporation of America. Jaffee is also President and General Manager of Amlan. “Kim joining our team of knowledgeable industry professionals will help strengthen our APEC operations and help our customers meet the evolving consumer demands for high-quality, natural animal protein.”

Kim is a graduate of South China Agricultural University, with both bachelor’s and master’s degrees in agricultural science. He earned a PhD from The University of Queensland specializing in the amino acid nutrition of broiler chickens.

Company Information

Amlan is the animal health business of Oil-Dri Corporation of America, leading global manufacturer and marketer of sorbent minerals. Oil-Dri leverages over 80 years of expertise in mineral science to selectively mine and process their unique mineral for consumer and business-to-business markets. Oil-Dri Corporation of America doing business as “Amlan International” is a publicly traded stock on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives across the world. Product availability may vary by country, associated claims do not constitute medical claims and may differ based on government requirements.

Reagan Culbertson
Media Contact
press@amlan.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b364b802-c976-4548-8537-63a222ec6507

Zenas BioPharma แต่งตั้ง Dr. John Orloff ให้ดำรงตำแหน่งกรรมการบริษัท

บอสตันและเซี่ยงไฮ้ จีน, Jan. 07, 2022 (GLOBE NEWSWIRE) — วันนี้ Zenas BioPharma บริษัทชีวเภสัชภัณฑ์ระดับโลกซึ่งมีความมุ่งมั่นที่จะเป็นผู้นำด้านการพัฒนาและการรักษาโดยใช้ภูมิคุ้มกันบำบัด ได้ประกาศแต่งตั้ง Dr. John Orloff ให้ดำรงตำแหน่งกรรมการบริษัท ทั้งนี้ Dr. Orloff ได้เข้าร่วมเป็นคณะกรรมการบริษัท Zenas ด้วยประสบการณ์ความสำเร็จกว่า 25 ปีในการเป็นผู้นำองค์กรด้านการวิจัยและการพัฒนาระดับโลกในด้านการรักษาโรคต่าง ๆ รวมถึงโรคแพ้ภูมิตัวเอง

“เรามีความยินดีเป็นอย่างยิ่งที่ได้ต้อนรับ Dr. Orloff ในฐานะกรรมการบริหารของ Zenas” Lonnie Moulder ผู้ก่อตั้งและประธานกรรมการบริหารของ Zenas กล่าว “ความเป็นผู้นำและความเชี่ยวชาญที่ครอบคลุมด้านการวิจัย การพัฒนา รวมถึงกิจการด้านการแพทย์และการกำกับดูแลของ Dr. Orloff เป็นสิ่งที่มีคุณค่าอย่างยิ่ง เนื่องจากเรากำลังพัฒนากลุ่มผลิตภัณฑ์ด้านการรักษาที่ทันสมัยโดยใช้ภูมิคุ้มกันบำบัด ตลอดจนขยายกลุ่มผลิตภัณฑ์ของเราอย่างต่อเนื่องในการพัฒนาธุรกิจ”

“ผมมีความยินดีที่จะได้ร่วมงานกับทีมผู้บริหารของ Zenas และกรรมการบริษัทท่านอื่น ๆ ในขณะที่บริษัทกำลังเร่งพัฒนากลุ่มผลิตภัณฑ์ด้านภูมิคุ้มกันที่มีประสิทธิภาพ” Dr. Orloff กล่าว “ผมหวังว่าจะได้มีส่วนร่วมในการพัฒนาอย่างต่อเนื่องของบริษัท ในขณะที่บริษัทมุ่งมั่นที่จะดำเนินภารกิจในการจัดหายาที่ใช้นวัตกรรมใหม่ให้กับผู้ป่วยที่จำเป็นต้องใช้ยาดังกล่าว”

ปัจจุบัน Dr. Orloff ปฏิบัติงานในฐานะพันธมิตรผู้ร่วมทุนของ Agent Capital และตำแหน่งผู้บริหารล่าสุดของท่านได้แก่ ตำแหน่งรองประธานบริหารและหัวหน้าฝ่ายวิจัยและพัฒนาของ Alexion โดยท่านทำหน้าที่บริหารงานเพื่อขยายกลุ่มผลิตภัณฑ์ในขั้นตอนการพัฒนาสำหรับ 30 โครงการ ซึ่งช่วยสนับสนุนการเข้าซื้อกิจการของ Alexion โดย AstraZeneca มูลค่า 39 พันล้านดอลลาร์เมื่อเร็ว ๆ นี้

ก่อนที่จะร่วมงานกับ Alexion Dr. Orloff ดำรงตำแหน่งหัวหน้าฝ่ายวิจัยและพัฒนาระดับโลกและประธานเจ้าหน้าที่ฝ่ายวิทยาศาสตร์ของ Baxalta และยังดำรงตำแหน่งผู้บริหารระดับสูงของ Novelion, Baxter International, Merck Serono, Novartis และ Merck Research Laboratories ทั้งนี้ก่อนที่จะเข้าสู่อุตสาหกรรมชีวเภสัชภัณฑ์ ท่านเป็นอาจารย์ที่คณะแพทยศาสตร์ มหาวิทยาลัยเยล Dr. Orloff สำเร็จการศึกษาระดับปริญญาตรีสาขาเคมีจากวิทยาลัยดาร์ทมัธ และสำเร็จการศึกษาระดับปริญญาตรีสาขาแพทยศาสตร์จากมหาวิทยาลัยเวอร์มอนต์ วิทยาลัยแพทยศาสตร์ จากนั้นจึงสำเร็จหลักสูตรด้านต่อมไร้ท่อและเมตาบอลิซึมที่คณะแพทยศาสตร์ มหาวิทยาลัยเยล

ข้อมูลเกี่ยวกับ Zenas BioPharma

Zenas BioPharma เป็นบริษัทชีวเภสัชภัณฑ์ระดับโลกที่มีสำนักงานอยู่ในสหรัฐอเมริกาและจีน โดยมีความมุ่งมั่นที่จะเป็นผู้นำด้านการพัฒนาและการรักษาโดยใช้ภูมิคุ้มกันบำบัดสำหรับผู้ป่วยในสหรัฐอเมริกา จีน และประเทศต่าง ๆ ทั่วโลก Zenas ได้เร่งพัฒนากลุ่มผลิตภัณฑ์การรักษาโดยใช้นวัตกรรมที่ทันสมัยซึ่งเติบโตอย่างต่อเนื่องตามกลยุทธ์การพัฒนาธุรกิจที่ประสบความสำเร็จของเรา ทีมผู้บริหารที่มีประสบการณ์และเครือข่ายพันธมิตรทางธุรกิจของเราดำเนินงานด้วยความเป็นเลิศในด้านการรักษาที่สามารถปรับเปลี่ยนได้ เพื่อช่วยพัฒนาคุณภาพชีวิตของผู้ป่วยโรคภูมิต้านตนเองและโรคหายาก หากต้องการข้อมูลเพิ่มเติมเกี่ยวกับ Zenas BioPharma โปรดเข้าไปที่ www.zenasbio.com และติดตามเราทาง Twitter ได้ที่ @ZenasBioPharma และ LinkedIn

สำหรับนักลงทุนและสื่อมวลชน โปรดติดต่อ:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Korean man jailed for six years for arranging illegal exit

The Hanoi People’s Court on January 7 sentenced Kang Joon-ho, a 74-year-old man from the Republic of Korea (RoK), to six years in prison for arranging illegal exit for Vietnamese citizens.

His two Vietnamese accomplices, Trinh Ba Huy, 36, residing in Hanoi’s outlying district of Chuong My and Pham Van Sang, 42, residing in Ha Dong district, were given 36 months on probation and 4 years behind bar, respectively, on the same charge.

On June 1, 2020, Hanoi’s police received documents about a case involving six residents in Chuong My district who sought to fly to the RoK’s Jeju island for work on tourism visas.

Five of them admitted that on October 5, 2019, they departed for Jeju but a man named Nguyen Van Doan was denied for exit at Noi Bai International Airport. The remaining five people were later forced to return home on October 9, 2019.

They said they were introduced by Huy to fly to the RoK as tourists, then seek jobs there.

Sang admitted that he previously helped Kang bring six others to Jeju from Tan Son Nhat International Airport in Ho Chi Minh City, who then stayed there for work.

Source: Vietnam News Agency

Expanded credit growth quota supports firms in recovery

The State Bank of Vietnam (SBV)’s expansion of credit growth quotas for commercial banks has created favourable conditions for lenders to boost lending, contributing to supporting capital sources for individuals and firms to recover after the COVID-19 pandemic.

According to the SBV, as of December 22, credit increased by 12.68 percent compared to the end of last year. Notably, the credit growth had increased significantly for the past few weeks as until November 25, the rise was only 10.1 percent.

This means trillions of Vietnamese dong of bank loans had been poured into production and business in the past few weeks when the country has gradually reopened after a long time under social distancing.

To meet rising capital demands at year-end, SBV last month extended credit growth quotas to 11 banks. TPBank had the highest rising rate of 6 percent, a jump from from 17.4 percent to 23.4 percent, thanks to its strong capital adequacy ratio (CAR) according to Basel II standards and a diverse investment portfolio.

Other banks, which were allowed to expand their credit room by roughly 4-5 percent last month, included Techcombank (from 17.1 percent to 22.1 percent), MSB (from 16 percent to 22 percent) and MB (from 15 percent to 21 percent).

Experts from the Vietcombank Securities Company (VCBS) forecast the SBV in 2022 will grant long-term credit growth quotas for some banks instead of announcing it every quarter as currently.

Currently, the SBV periodically assesses and modifies the credit growth quota for each bank based on its CAR, financial strength, risk governance and operational status.

Besides, banks that do not focus lending on hazardous and vulnerable businesses and offer low lending interest rates will get the SBV priority in having higher credit growth quotas.

With the criteria, VCBS experts expected banks such as TCB, TPB, VPB, MBB, ACB, HDB, VIB and MSB will receive long-term credit growth quotas higher than the average rate.

Banking expert Nguyen Tri Hieu said the central bank was likely to extend long-term credit growth quotas for some banks next year thanks to a significant rise of retail credit, which will remain a main growth driver for the banking system in the year.

According to the SBV, the proportion of retail credit has increased from 31 percent in 2015 to 42 percent of total outstanding loans at the end of the third quarter of 2021.

Hieu explained the country’s rising proportion of workers with high-income jobs, especially in foreign direct investment (FDI) firms, would help promote the demand for consumer loans. This is also a criterion for the SBV to expand long-term credit growth quotas for some banks.

According to the SBV’s Deputy Governor Dao Minh Tu, the SBV will increase the credit growth target for 2022 to around 14 percent against 12 percent in 2021. However, the rate might be adjusted flexibly in its operational approach.

The Government has so far also required the whole banking industry to implement effective credit policies to support the development of production and business and the recovery of the economy after the pandemic.

Besides commitments to increase capital for priority industries and sectors, Tu noted the banking system would apply stringent control over at-risk businesses, particularly in keeping a firm hand over their real estate assets, risky corporate bonds and their stocks.

The central bank will take steps to closely monitor credit flows to the real estate and securities industries, he said, adding that loans used for speculative reasons, which caused market volatility in the industries would be restricted.

However, he noted, the SBV would continue to prioritise and provide favourable conditions for the residential real estate sector to address genuine consumer demands. Besides, the capital flows for the healthy and stable development of the securities market would also be encouraged.

Source: Vietnam News Agency

Railway sector asked to reform mindset to boost development

Deputy Prime Minister Le Van Thanh has requested the Vietnam Railway Corporation (VNR) to make drastic reforms so as to address shortcomings and develop the sector further in the time ahead.

The Government Office on January 6 released an announcement of the Deputy PM’s conclusion at a recent meeting on rail transport.

According to the document, the railway sector is facing an array of difficulties and challenges: the national infrastructure in this field has yet to receive due investment, the sector’s market share been shrinking while road and air transport booming, and the lingering COVID-19 pandemic greatly affected infrastructure upgrade, rail transportation of passengers, as well as the VNR’s performance.

As the pandemic remains complicated, Deputy PM Thanh told the VNR to reform its mindset, take more drastic and proactive moves, and adopt new solutions and methodology to deal with outstanding problems and strongly develop the sector in the time ahead.

The State-owned enterprise should bravely propose breakthrough mechanisms, policies and solutions, turn difficulties and challenges into opportunities for development in the new context, conduct flexible transformation, and promptly build a new business plan to optimise advantages of rail freight transportation to give timely assistance to other modes of transport.

More attention should be paid to railway infrastructure development and efforts made to attract private resources to rail transport.

Meanwhile, the Ministry of Transport and related ministries and agencies need to prioritise investment for railway infrastructure and tackle difficulties to facilitate the sector’s development, the Deputy PM said.

Source: Vietnam News Agency